Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients

Data from a retrospective, single-center study of 829 patients with bcr-abl-negative MPNs, after a median follow-up of 5.5 years, suggest that these patients have a significantly increased risk of bleeding events while receiving anticoagulation (HR 4.06 [2.32, 7.09]) or antiplatelet (HR 2.31 [1.43, 3.71]) treatments. Other factors, including age, sex, and mutational status, were not associated with bleeding risk.